 (range, 8-68) and 33 (range, 4-76) 
iNtRODUCtiON
Chordoma is a rare tumour arising from the remnants of the ectopic notochord. According to the Surveillance, Epidemiology, and End Results (SEER) database, the annual incidence of chordoma was 0.08 per 100,000 population in the United States. Chordoma can arise from the skull base (32%), mobile spine (32.8%), or sacral spine (29.2%). 1 It is a low-grade neoplasm but has a locally aggressive biological course; its onset is insidious and usually involves critical neural and bony structures at presentation. 2 Local data on the clinical, pathological, and treatment outcome of chordoma are limited. We report our hospital's experience in treating chordoma over a 17-year period.
MEtHODS
This was a retrospective review of clinicopathological characteristics and treatment outcome of patients with chordoma at a single institution. It has been approved by the ethics committee. Informed consent from patients was not required. All consecutive patients with chordoma treated in our hospital between January 2000 and June 2016 were reviewed through the hospital database. Their demographic, clinical, and pathological data were collected. Duration of follow-up and survival were calculated from the first date of histological diagnosis to the most-recent visit or death. Statistical analyses were conducted using the Statistical Package for the Social Sciences (Windows version 21.0; IBM, Armonk [NY], US). The Kaplan-Meier curve was used to describe local control and overall survival rates.
RESUltS tumour Characteristics
We identified 25 patients (one Caucasian and 24 Chinese) with chordoma, of whom 14 were of skull base and 11 of sacral origin (Table 1 and Figure 1 ). The median age at diagnosis was 41 (range, 22-73) and 64 (range, 45-75) years, respectively. The median tumour size at diagnosis was 42.5 (range, 22-65) and 104 (range, 50-148) mm, respectively. One patient with sacral chordoma had distant metastasis to lungs upon presentation. Of the patients, 11 of 14 skull base and all 11 sacral cases were conventional chordoma; the remaining three skull base chordomas were of chondroid variant. No dedifferentiation was observed. The Ki-67 proliferation index was not assessed.
Primary treatment
In the skull base chordoma cohort, all 14 patients underwent surgery (five of them underwent two-stage surgery) but none achieved R0 resection. Adjuvant radiotherapy was given to 13 patients, of whom two received adjuvant stereotactic radiosurgery using the Gamma Knife with dosage of 16 Gy in a single fraction (n = 1) and 17 Gy in a single fraction (n = 1). The prescribed dose and technique for the remaining 11 patients were 50.4 Gy in 28 Fr (n = 2, intensitymodulated radiotherapy), 50 Gy in 25 Fr (n = 1,
除。4名患者接受術後放療。5年局部控制率分別為29.6%和17.9%。瘤擴散的中位時間分別為42（範
圍：8-68）和33（範圍：4-76）個月。5年總存活率分別為64.3%和72.2%。 In the sacral chordoma cohort, eight of the 11 patients underwent surgery and three of them achieved R0 resection, with the closest resection margin being 0.7, 2, and 4.5 mm. One patient refused surgery and received only palliative radiotherapy (30 Gy in 5 Fr) using the conformal technique. The remaining two patients refused both surgery and radiotherapy and were excluded from the analysis of treatment outcome. Four of the eight operated patients received postoperative radiotherapy given to a dose of 50 Gy in 25 Fr (n = 1, conformal technique), 60 Gy in 30 Fr (n = 1, intensitymodulated radiotherapy; n = 1, TomoTherapy), 28 Gy in 7 Fr (n = 1, conformal technique; the patient declined radical radiotherapy after subtotal resection).
結論：本院治療脊索瘤的效果不理想。應該探索改善療效的策略。

Outcome
In the skull base chordoma cohort, the median followup was 70 (range, 4-168) months. The median time to progression was 42 (range, 8-68) months. Of the 14 patients, 10 had local progression; none developed regional or distant metastasis. The actuarial 5-year local control rate was 29.6% ( Figure 2 ). After surgery, seven patients had persistent cranial nerve palsies and one patient had right upper limb monoparesis. In the sacral chordoma cohort, the median followup was 33 (range, 4-76) months. The median time to progression was 27 (range, 10-29) months. Five patients had local progression; one of them also had new nodal metastasis and another also had new bone metastasis. The actuarial 5-year local control rate was 17.9% ( Figure 2 ). Among the eight surgically treated patients, five had wound infection or dehiscence and required debridement and flap closure, two developed ipsilateral foot drop and sensory loss, and one became paraplegic and bedbound.
Respectively for the 10 skull base and five sacral chordoma patients with local progression, the median dose of adjuvant radiotherapy was 50 Gy in 25 Fr and 60 Gy in 30 Fr (Table 2 ). Tumour size, tumour site, resection margin (negative vs. positive), postoperative radiotherapy, volume of residual tumour (>20 cm 3 vs. <20 cm 3 ), and gender were not prognostic for the rate of local control or overall survival (p > 0.05, log rank test).
Salvage treatment and Outcome
Eight of the 10 skull base chordoma patients with local progression underwent salvage surgery and three achieved R1 resection. Two patients received postoperative radiotherapy after salvage surgery: one received his first course adjuvant radiotherapy 60 Gy in 30 Fr after R1 resection, and the other patient received a second-course adjuvant stereotactic radiosurgery in another institution after R2 resection with no details available. Five of the eight patients had further progression; the median time to progression after salvage treatment was 33 (range, 4-51) months.
None of the five sacral chordoma patients with local progression underwent salvage surgery. Three of them received palliative radiotherapy with dosage of 24 Gy in 4 Fr (n = 1), 28 Gy in 7 Fr (n = 1), and 30 Gy in 5 Fr (n = 1). Two patients had further progression and one of them also had distant metastasis to the abdominal wall; the median time to progression after salvage treatment was 18 (range, 10-82) months.
Of the total 10 deaths in the two cohorts, three died of chordoma and two died of treatment complication (Table 3 ). The 5-year overall survival was 64.3% and 72.2% for the skull base and sacral chordoma cohorts, respectively ( Figure 2) ; the median overall survival for sacral chordoma was 5.3 years, while it was not yet reached for skull base chordoma.
DiSCUSSiON
Chordoma is an uncommon tumour entity. To our knowledge, this is the first local study reported in the literature. Consistent with other reports, 1,3,4 our study shows that chordoma predominantly affects males. The median age of onset is younger for skull base chordoma, whereas sacral chordoma tends to affect older patients. 1 All our patients had conventional chordoma, except for three patients who had the chondroid variant, all originating from the skull base. No significant progression-free survival and overall survival differences were observed between conventional type and chondroid variant in our cohort. The results are comparable to other reports which show that the chondroid variant usually arises from the skull base region and has a similar prognosis to conventional chordoma. 4, 5 From the literature, histological dedifferentiation was evident in 2% to 8% of chordoma and portended a poorer prognosis. 6 We did not identify such histological transformation in our cohort. The most common presenting symptom of our patients was cranial nerve palsy (78.6%) in the skull base cohort and low back pain (45.5%) in the sacral cohort, consistent with the literature. 2 In contrast to the SEER database, none of our patients had chordoma arising from the thoracic or lumbar spine. This could be due to ethnic differences.
Although chordoma tends to grow slowly, local progression can be devastating. Skull base chordoma can lead to invasion and compression of the brainstem, whereas sacral chordoma can cause paraplegia, compromise mobility, and potentially increase opportunistic infections. Local control is therefore crucial for cure, quality of life, and survival. Our reported 5-year local control rates for both skull base and sacral chordoma cohorts, 29.6% and 17.9% respectively, are lower than the 65% reported in other studies. 3, 7, 8 To elucidate the reasons behind the lower local control rates of our patient cohorts, the local control rates need to correlate with the tumour characteristics and the treatment in this report.
Inadequate resection margin is associated with a higher rate of local recurrence in sacral chordoma. [8] [9] [10] En-bloc excision with wide negative margin is therefore the gold standard of treatment. 2 In our sacral chordoma cohort, five (62.5%) of the eight patients had involved margin or gross residual tumour after primary surgery. This is substantially higher than the 30% reported in other studies. 10, 11 We attribute this to the possible late presentation of our patients, as reflected by the larger median preoperative tumour size (10 cm vs. 8 cm) than those reported. 10, 11 Larger sacral chordoma have often already invaded nearby soft tissues and structures that makes R0 resection with wide clear margins infeasible. The proximal location of sacral chordoma in the S1-2 region has no impact on local control, although this is often associated with a higher risk of perioperative morbidities and neurological deficits. 8 Public education and raising awareness of early presenting symptoms of persistent sacral pain, as well as prompt investigations and surgery upon diagnosis by surgeons are warranted. Being a chemo-and radio-resistant tumour, preoperative radiotherapy or targeted therapy has not been reported to improve the rates of R0 resection or local control. None of our patients with local progression was offered second surgery because it is associated with increased morbidity due to extensive scarring and difficulty in establishing tissue planes. 8 Irrespective of salvage treatment, the outcome for recurrent sacral chordoma remains poor. 12 Gross total resection is the optimal treatment for skull base chordoma. 13 Nonetheless, this is difficult to achieve because of its proximity to critical neurological structures and deep location. To preserve neurological function, subtotal resection is often inevitable.
2,3 The rate of gross total resection has been reported to be 12% to 33%, 3, 7, 14 but gross total removal could not be achieved in any of our patients.
Chordoma is known to be radioresistant. Although there is no definite dose-response relationship identified, 15 the local control using conventional photon beam treatment at a dose up to 60 Gy in 30 Fr is unsatisfactory, especially when gross disease is present. The reported 5-year progression-free survival of around 25% in the literature 16 for such patients is comparable to the 30% in our cohort. The highest radiation dose received by those who had local progression in the current report was 60 Gy in 30 Fr. For skull base chordoma, radiotherapy dose is often limited by organs at risk around the tumour, particularly the brainstem, optic chiasm, and spinal cord. As residual tumour is inevitable, postoperative radiotherapy is a standard treatment. With the advent of protons or charged particle treatment, higher doses of radiation can be delivered to the target volume, while restricting radiation dose to the organs at risk within safe limits. 2 However, these modalities of radiation treatment are not commonly available in the Asia Pacific region. In a study of image-guided intensity-modulated radiotherapy (median dose, 76 Gy in 38 Fr) for skull base chordoma, its rates of local control and late toxicity were similar to those of protonbased radiation. 3 Besides the prescribed radiation dose, the postoperative gross tumour volume in skull base chordoma also predicts treatment outcome. Reports have shown that a large gross tumour volume, in the range of 10-30 cm 3 , is associated with poor local control despite high-dose postoperative radiotherapy. 7, 17, 18 Small residual tumours, on the other hand, can be treated with stereotactic radiosurgery and achieve good results. 18 In our skull base cohort, after excluding four patients with missing gross tumour volume data, five of the nine patients have the gross tumour volume of >20 cm 3 . The median postoperative gross tumour volume was 20.8 (range, 0-76.8) cm 3 , which was substantially larger than the reported median of 8-15cm 3 in other studies. 3, 7 The larger pre-radiation gross tumour volume in our patients may have adversely affected treatment outcome.
As most studies on postoperative radiotherapy were reported in skull base chordoma, the indication of adjuvant radiotherapy after en-bloc resection with wide negative margin in sacral chordoma is less well defined. In our sacral chordoma cohort, one patient developed local progression 2 years after R0 resection alone (the closest margin was 4.5 mm). Another patient who had R0 resection alone with a tighter margin of 2 mm showed no evidence of disease progression after 5.5 years. Nonetheless, given the poor prognosis of recurrence, adjuvant radiotherapy was commonly used in most case studies reported, especially when the tumour is not grossly resected. More clinical studies are warranted to address the role of adjuvant radiotherapy after complete surgical resection in sacral chordoma.
Up to 30% of patients with chordoma have metastasis, predominantly those with sacral chordoma. The common sites of metastasis are the skin and bone, followed by lymph nodes and lung. 19 The elevated Ki67 proliferation index (>5%) in the primary tumour may help predict a more aggressive clinical course and shorter survival. 9, 20 None of the patients with metastasis received systemic treatment. Although insensitive to chemotherapy, chordoma has activated platelet-derived growth factor receptor and responds to imatinib (a multi-targeted tyrosine-kinase inhibitor) with symptom improvement and disease control in a phase II study.
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CONClUSiON
Chordoma is rare in the Hong Kong Chinese population. Its local control remains a challenge when the tumour is large. Complete resection with wide margins and dose escalation of adjuvant radiotherapy may improve treatment outcome. New targeted therapy may be beneficial in patients with distant metastasis or inoperable progression. More comprehensive data will help refine the optimal treatment strategies for chordoma.
